1/3

FIEO Registered Export Ready

Glimepiride & Metformin Hydrochloride (SR) Tablets CDPRIDE-M1 10x10 Tablets

Name: Glimepiride & Metformin Hydrochloride (SR) Tablets CDPRIDE-M1 10x10 Tablets
Brand: cd&m remedies
SKU: 8644363
Availability: InStoreOnly

Sold by cd and m remedies private limited · Contractor, Distributor, Wholesaler · Kanpur, Uttar Pradesh, India

Price

Price on request

In stock

Minimum order: 1 unit

Export Snapshot

MOQ

1 unit

Lead time

On request

Packaging

Standard export packaging

Shelf life / longevity

As per product specification

HSN Code

300490

Origin

India

Port of dispatch

On request

Export markets served

Global markets

Values shown are for cd and m remedies private limited.

FIEO Registered

Suitable for

Importers · Distributors · Wholesalers

Kanpur Dispatch on request FIEO member

cd and m remedies private limited

Contractor, Distributor, Wholesaler · Kanpur, Uttar Pradesh, India

we are currently a wholesale price distributor based in India . we can supply any and all allopathic drugs and also are involved in taking your valuable manufacturing orders for all tablets, capsules, injections, syrups. our focus is to give our best service to people through export and we work hard for our customers.

Registered address: Kanpur Nagar, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Other.

View profile All products

Established

2016

Employees

1–10

GST

09AAGCC4412K1ZN

IEC code

Not shared

Export markets

Global markets

GlobalLinker Member Since

Aug 2025

Turnover

$250,000 - $1 MM

Incorporation Type

On request

Certifications & Awards

DRUG LICENSE GST IMPORT EXPORT CERTIFICATE

Product details

What are the specifications of this product?

Overview

Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1 is a pharmacopeia-grade tablets formulation manufactured by CD&M Remedies, containing Glimepiride IP 1 mg + Metformin Hydrochloride IP 500 mg (sustained release). Formulated to Indian Pharmacopoeia (IP) specifications, this sulfonylurea-biguanide combination tablet is supplied in 10x10 Tablets export packing suitable for international wholesale and distribution. The product is positioned for B2B buyers seeking a reliable type 2 diabetes combination therapy medication for institutional, hospital, or retail pharmacy supply chains. CD&M Remedies maintains consistent batch-to-batch quality control, making this fixed-dose antidiabetic tablet a dependable addition to a pharmaceutical importer's product portfolio.Features:Composition: Glimepiride IP 1 mg + Metformin Hydrochloride IP 500 mg (sustained release)Manufactured to Indian Pharmacopoeia (IP) standards for consistent qualityAvailable in tablets form for ease of storage, handling, and dispensingSupplied by CD&M Remedies, an established pharmaceutical manufacturer and exporterExport-ready 10x10 Tablets packing designed for bulk international shipmentSuitable for wholesale distribution to pharmacies, hospitals, and healthcare institutionsAttributes:Brand / Seller: CD&M RemediesProduct Category: Anti-Diabetic Combination MedicationDosage Form: TabletsPack Size: 10x10 TabletsPharmacopeial Standard: Indian Pharmacopoeia (IP)Product Code: 1004

Product Description

Product Overview

This fixed-dose combination pairs Glimepiride, a sulfonylurea insulin secretagogue, with sustained-release Metformin Hydrochloride, a biguanide, to support comprehensive glycemic management in type 2 diabetes mellitus.

Composition & Specifications

Each unit of this sulfonylurea-biguanide combination tablet contains Glimepiride IP 1 mg + Metformin Hydrochloride IP 500 mg (sustained release), formulated in tablets form and manufactured in compliance with Indian Pharmacopoeia (IP) standards. This ensures uniform potency and quality across every production batch, a key requirement for pharmaceutical importers and distributors evaluating type 2 diabetes combination therapy medication for their regional markets.

Application & Usage

Intended for the management of type 2 diabetes mellitus where combination therapy is clinically indicated. For distribution to pharmacies, hospitals, and diabetes care centers under medical supervision.

Packaging & Export Readiness

Supplied in 10x10 blister strips, offering a stable and export-friendly packaging format. The 10x10 Tablets configuration is widely used in international pharmaceutical trade, supporting efficient inventory management for wholesalers and institutional buyers sourcing fixed-dose antidiabetic tablet in bulk quantities.

Why Source From CD&M Remedies

CD&M Remedies is an established manufacturer of IP-compliant pharmaceutical formulations, supplying sulfonylurea-biguanide combination tablet to B2B buyers and importers worldwide. Buyers benefit from consistent formulation quality, reliable supply capability, and export-oriented packing suited to cross-border pharmaceutical trade.

Q: What is the composition of Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1?
A: It contains Glimepiride IP 1 mg + Metformin Hydrochloride IP 500 mg (sustained release), manufactured to Indian Pharmacopoeia (IP) standards in tablets form.

Q: What pack sizes are available for Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1?
A: This product is supplied in 10x10 Tablets export packing, suitable for wholesale and institutional bulk orders.

Q: Who manufactures Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1?
A: Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1 is manufactured and supplied by CD&M Remedies, under product code 1004.

Q: Which product category does Glimepiride And Metformin Hydrochloride Sustained Release Tablets Cdpride-M1 belong to?
A: It falls under the Anti-Diabetic Combination Medication category, intended for B2B pharmaceutical buyers and importers.

Description provided by cd and m remedies private limited.

Specifications

Product Title	Glimepiride & Metformin Hydrochloride (SR) Tablets CDPRIDE-M1 10x10 Tablets
Brand / Seller	CD&M Remedies
Manufacturer	CD AND M REMEDIES PRIVATE LIMITED
Composition	Glimepiride IP 1 mg + Metformin Hydrochloride IP 500 mg (sustained release)
Dosage Form	Tablets
Release Type	Sustained Release (SR)
Pharmacopeial Standard	Indian Pharmacopoeia (IP)
Pack Size	10x10 Tablets
Packaging Type	Export packing / blister strips
Product Category	Anti-Diabetic Combination Medication
Intended Use	Type 2 diabetes mellitus management under medical supervision
Supply Channel	Wholesale / institutional / export
Product Code	1004
Minimum Order Quantity	1

Use cases

Category	Antidiabetic Combination Tablets
Primary application	Wholesale, distribution, and international sourcing
Brand	cd&m remedies
Product type	Product

Logistics & handling

Lead time	On request
Packaging	As per buyer requirement
Storage condition	As recommended by supplier
Origin	India
Form	As listed by supplier

Commercials (this seller)

Minimum order	1 unit
Lead time	On request
Payment terms	As per negotiated commercial agreement.

Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing Glimepiride & Metformin Hydrochloride (SR) Tablets CDPRIDE-M1 10x10 Tablets. Answers compiled from verified sellers' commercial terms and platform data.

Q: What is the composition of CDPRIDE-M1 tablets?

A: Each tablet contains Glimepiride IP 1 mg plus Metformin Hydrochloride IP 500 mg in sustained release form.

Q: What pharmacopeial standard does this product follow?

A: It is manufactured to Indian Pharmacopoeia (IP) specifications.

Q: What is the pack size for export and wholesale supply?

A: The product is supplied in 10x10 Tablets export packing.

Q: Is this product suitable for institutional procurement?

A: Yes, it is positioned for wholesale distribution to pharmacies, hospitals, and healthcare institutions.

Q: What is the dosage form of this medicine?

A: It is supplied as tablets, which are easier to store, handle, and dispense in pharmacy supply chains.

Q: What is the intended therapeutic use?

A: It is intended for the management of type 2 diabetes mellitus where combination therapy is clinically indicated.